Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
McKesson
Colorcon
Express Scripts
Boehringer Ingelheim

Last Updated: July 1, 2022

CLINICAL TRIALS PROFILE FOR MAVENCLAD


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Mavenclad

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03150004 ↗ Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia Recruiting Medical College of Wisconsin Phase 2 2017-06-14 This is a prospective phase II clinical study to be conducted at the Medical College of Wisconsin. After meeting the study criteria and enrollment, patients will be treated with Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) chemotherapy and followed at periodic intervals to determine the primary and secondary objectives.
NCT03364036 ↗ Evaluation of the Onset of Action in Highly Active MS (MAGNIFY) Active, not recruiting Merck KGaA, Darmstadt, Germany Phase 4 2018-05-28 The main purpose of the study was to determine the onset of Mavenclad® action by frequent magnetic resonance imaging (MRI) assessment of the combined unique active (CUA) lesions in participants with highly active relapsing multiple sclerosis (MS).
NCT03369665 ↗ Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS) Active, not recruiting Merck KGaA, Darmstadt, Germany Phase 4 2018-06-20 The main purpose of the study is to assess the health-related quality of life (HRQoL) through the Multiple Sclerosis Quality of Life-54 Questionnaire (MSQoL-54) scale in highly-active relapsing multiple sclerosis (RMS) subjects treated with Mavenclad® for 2 years (24 months).
NCT03441048 ↗ Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia Recruiting Medical College of Wisconsin Phase 1 2018-05-22 This is a prospective, single-center phase I clinical study aimed at determining the maximum-tolerated dose and safety of Lintuzumab-Ac225 in combination with CLAG-M chemotherapy in the management of relapsed/refractory acute myeloid leukemia. This study uses a 3+3 design to estimate the maximum-tolerated dose (MTD).
NCT04121403 ↗ Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) Recruiting Göteborg University Phase 3 2019-10-16 The main aim and overall objective of the study is to assess whether rituximab is non-inferior to cladribine for the treatment of relapsing MS. Secondly, the investigators will test specific blood and MRI biomarkers that may contribute to future personalized treatment for MS patients. Furthermore, the investigators want to evaluate the health economic consequences of the two therapies.
NCT04121403 ↗ Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) Recruiting Helse Forde Phase 3 2019-10-16 The main aim and overall objective of the study is to assess whether rituximab is non-inferior to cladribine for the treatment of relapsing MS. Secondly, the investigators will test specific blood and MRI biomarkers that may contribute to future personalized treatment for MS patients. Furthermore, the investigators want to evaluate the health economic consequences of the two therapies.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Mavenclad

Condition Name

Condition Name for Mavenclad
Intervention Trials
Multiple Sclerosis 7
Acute Myeloid Leukemia 2
Advanced Multiple Sclerosis 1
Progressive Multiple Sclerosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Mavenclad
Intervention Trials
Multiple Sclerosis 8
Sclerosis 7
Leukemia, Myeloid, Acute 2
Leukemia, Myeloid 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Mavenclad

Trials by Country

Trials by Country for Mavenclad
Location Trials
Norway 11
Czechia 5
France 5
Spain 5
Poland 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Mavenclad
Location Trials
Wisconsin 2
New York 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Mavenclad

Clinical Trial Phase

Clinical Trial Phase for Mavenclad
Clinical Trial Phase Trials
Phase 4 6
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Mavenclad
Clinical Trial Phase Trials
Recruiting 7
Active, not recruiting 2
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Mavenclad

Sponsor Name

Sponsor Name for Mavenclad
Sponsor Trials
Medical College of Wisconsin 2
Merck KGaA, Darmstadt, Germany 2
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Mavenclad
Sponsor Trials
Other 23
Industry 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Medtronic
Mallinckrodt
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.